IQVIA climbs after raising annual profit forecast
IQV•Analyst view on demand
Evercore ISI analyst Elizabeth Anderson says IQVIA's stronger-than-expected 1.22x book-to-bill ratio, which compares new orders with revenue recognized, points to improving demand for outsourced drug development services.
Shares rise after guidance and results beat estimates
Shares of contract research firm IQVIA Holdings IQV.N rise 13.6% to $242
Company raises FY2026 adjusted profit forecast to $12.80 to $13.00/share from prior forecast of $12.65 to $12.95/share
New forecast midpoint of $12.90/share, above analysts' estimate of $12.80/share - LSEG data
Company's Q2 revenue of $4.37 bln tops analysts' average expectation of $4.30 bln - LSEG data
Reports Q2 adjusted profit of $3.15/share vs analysts' average estimate of $3.03/share - LSEG data
Including session's move, stock up ~7% YTD
